Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-828 (Telminuvo) vs Coadministration in Healthy Volunteers
NCT02358824Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + levamlodipine in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the Last Measurable Concentration. Started Feb 2015; status: completed.
02
Drugs
telmisartan + levamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02358824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358824.